Navigation Links
Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures
Date:12/16/2008

LOS GATOS, Calif., Dec. 16 /PRNewswire/ -- TriCipher will host an informative Webinar detailing the cost cutting capabilities of digital signatures for the pharmaceutical and health care industries and strategies for securing digital signatures as more business processes transition online. The one hour webinar on December 16th brings together executives from SAFE- BioPharma Association and Pfizer who will discuss how digital signatures have benefited and streamlined research processes.

"Digital signatures represent the 'last mile' in moving business processes online for the pharmaceutical and health care industries," said Jon Brody, vice president of marketing at TriCipher. "Through the work of industry associations like SAFE-BioPharma and enabling technology companies like TriCipher, it's now possible to bridge that gap."

    Participants that attend the Webinar will learn:

     --   How businesses have saved hundreds of thousands of dollars by no
          longer needing to handle paper-based signatures
     --   The benefits of streamlining submissions to FDA and other regulatory
          agencies
     --   Strategies for protecting intellectual property and delivering a
          long term solution to IP preservation
     --   The 'Green' benefits of digital signatures


     WHO:      Mollie Shields-Uehling, president and CEO, SAFE-BioPharma
               Association
               William Barnes, Director of Identity Services, Pfizer
               Jon Brody, vice president of marketing, TriCipher
               A managing director of identity services at a leading
               international systems integrator
     WHAT:     "Cutting Costs with Digital Signatures in the Biopharmaceutical
               Industry"
     WHEN:     Tuesday, December 16th, 11 a.m. - 12 p.m. PT
     WHERE:    To register please visit:
              https://www2.gotomeeting.com/register/792964500

The webinar will include a brief demonstration of digital signatures using TriCipher's MySignatureBook with SAFE-BioPharma credentials. For more information on MySignatureBook and the webinar, please visit http://www.Tricipher.com.

About TriCipher

TriCipher, Inc. provides a unified authentication infrastructure to protect web and enterprise portals, the people that use them and the business process that flows through them against fraud and identity theft. The TriCipher Armored Credential System(TM) (TACS) is the first authentication system that enables companies to deploy and manage multiple types of credentials from a single infrastructure. Through this flexible "Authentication Ladder," TriCipher protects customer investment by adjusting authentication strength to defeat new threats and to meet regulatory changes without the need to implement a new infrastructure. Recently, TriCipher introduced myOneLogin(TM) the first secure on-demand offering that delivers strong authentication, single sign-on (SSO) convenience and the ability to seamlessly integrate multiple Software as a Service (SaaS) applications in a single solution. Founded in 2000, TriCipher is headquartered in Los Gatos, Calif. The company is funded by ArrowPath Venture Capital, EPIC Ventures, Intel Capital, RBC Technology Ventures, and Trident Capital. For more information, visit TriCipher on the web at http://www.tricipher.com.

About MySignatureBook

TriCipher MySignatureBook(TM) is a web-based digital signing solution that gathers multiple signatures from a centrally managed, Web-based workflow to a single, unaltered document. MySignatureBook ensures end-to-end security for highly regulated and sensitive documents, and eliminates time-consuming and costly paper-based signature processes, including shipping and storage. MySignaureBook supports a range of MSB supports a variety of strong credentials, including TriCipher clientless credentials, SAFE(TM) credentials, TriCipher ID Tool and ID Tool ToGo and any PKCS#11 digital credential. A robust web services interface makes it easy to integrate MSB with a variety of applications and document management systems.

About SAFE-BioPharma Association

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma(TM) digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma's vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association's members include Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, , Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, visit http://www.safe-biopharma.org.

SAFE-BioPharma(TM) is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

All product and company names herein may be trademarks of their registered owners.


'/>"/>
SOURCE TriCipher, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the ... and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the collaboration, ... facilities as a way to accommodate a more certain time frame for donor families ...
(Date:2/12/2016)... ... February 12, 2016 , ... J ... communities by continuing it’s commitment to act as Agents of Change in the ... closely with area homeless families to fulfill immediate needs and help them move ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... High-Cost Drug Categories: Strategies for Health Plans and PBMs,” an upcoming Feb. 24 ... maintain affordability and access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis ...
(Date:2/12/2016)... , ... February 12, 2016 , ... A lot has ... 35 years. A president has access to health and wellness resources most Americans could ... world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... Middletown, N.J. (PRWEB) , ... February 12, 2016 ... ... Americans is creating explosive growth in the field of long term care. With ... heightened demand for well-trained healthcare professionals in administrative roles in long term care ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)... ALISO VIEJO , Kalifornien, 12. Februar 2016 ... es mit der Aufnahme von Patienten für eine ... Embolisation von Aneurysmen („WEB") speziell für die Behandlung ... Laurent Spelle , MD, Leiter der Neuroradiologie an ... , Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ...
(Date:2/12/2016)... , Feb. 12, 2016 On Thursday, ... Robotic Surgery at St. David,s North Austin Medical Center ... Vinci ® Xi ® Surgical System with ... 7000dV. Thiru Lakshman , M.D., colorectal surgeon ... total proctocolectomy utilizing Integrated Table Motion technology, which seamlessly ...
Breaking Medicine Technology: